Dihexa Research Guide

01 What Is Dihexa?

Dihexa (formally N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a peptidomimetic compound developed at Washington State University College of Medical Sciences. It was engineered as a small-molecule analogue designed to mimic and amplify the activity of hepatocyte growth factor (HGF) at its receptor, MET — a signalling axis critical to synaptogenesis and neuroplasticity in the central nervous system.

Unlike most peptides in the nootropic research space, Dihexa is not derived from endogenous peptides or neuropeptide fragments. Instead, it was rationally designed using structure-activity relationship (SAR) data to produce a compound capable of crossing the blood-brain barrier and activating neurogenic signalling at extraordinarily low concentrations.

02 HGF/MET Mechanism

The hepatocyte growth factor (HGF) and its receptor MET (also called c-Met) form one of the most potent pro-neuroplasticity signalling axes in the CNS. HGF/MET activation drives:

• Synaptogenesis — formation of new synaptic connections between neurons
• Dendritic arborisation — increased branching complexity of dendrites
• Axonal guidance and growth — directed neurite extension
• Neuronal survival — anti-apoptotic signalling in stressed neurons

In Alzheimer's disease and other neurodegenerative conditions, HGF/MET signalling is significantly downregulated in hippocampal and cortical tissue — regions critical to memory formation and executive function. Preclinical research from the Washington State group demonstrated that systemic Dihexa administration restored dendritic spine density and synaptic connectivity in aged rodent hippocampal tissue to levels comparable to young controls.

Importantly, Dihexa does not act by increasing HGF protein levels. It acts as a direct small-molecule agonist at the MET receptor, bypassing the requirement for ligand availability — which declines with age.

03 BDNF Potentiation

Brain-derived neurotrophic factor (BDNF) is widely considered the master regulator of neuroplasticity. It promotes long-term potentiation (LTP), the cellular correlate of learning and memory. BDNF signals primarily through the TrkB receptor, triggering downstream cascades including PI3K/Akt, MAPK/ERK, and PLCγ — all of which converge on synaptic strengthening and neuronal survival.

Dihexa has been shown in preclinical assays to potentiate BDNF/TrkB signalling — meaning it amplifies the response to available BDNF rather than replacing it. This is mechanistically distinct from compounds that simply increase BDNF expression (such as exercise or certain antidepressants). The synergistic combination of direct MET agonism plus TrkB potentiation makes Dihexa's neuroplasticity profile unusually broad for a single compound.

BDNF Decline with Aging

Hippocampal BDNF expression declines by approximately 30–50% between young adulthood and old age in rodent models, paralleling deterioration in spatial memory performance on the Morris water maze. Dihexa-treated aged rodents showed significant reversal of both the BDNF-associated signalling deficit and the behavioural decline — without the safety concerns of direct BDNF protein administration (which causes pain hypersensitivity and cannot cross the BBB).

04 Synaptogenesis Data

The most striking preclinical data for Dihexa concerns its capacity to promote synaptogenesis at extraordinarily low concentrations. In in vitro assays using hippocampal neurons:

This differential is not simply an in vitro artefact. In vivo rodent studies using intranasal and subcutaneous administration both produced measurable increases in synaptic puncta density in hippocampal CA1 and CA3 regions — the areas most relevant to episodic memory formation and spatial navigation.

Dendritic spine density measurements via Golgi staining in aged rodents showed statistically significant increases following Dihexa treatment, reversing the dendritic pruning that accompanies normal aging in both rodents and humans.

05 Cognitive Studies

Rodent behavioural studies of Dihexa have used several validated cognitive paradigms:

Morris Water Maze

The Morris water maze tests hippocampal-dependent spatial learning and memory. Aged rodents treated with Dihexa showed acquisition curves statistically indistinguishable from young control animals, while vehicle-treated aged animals showed the expected impairment. This is among the most robust cognitive endpoints in rodent research.

Novel Object Recognition

NOR tasks evaluate recognition memory dependent on perirhinal cortex and hippocampal circuitry. Dihexa-treated aged rodents showed significantly higher discrimination indices compared to controls, indicating preserved recognition memory encoding and retrieval.

Alzheimer's Model Studies

In rodent models using scopolamine-induced amnesia (cholinergic blockade) and streptozotocin-induced cognitive impairment, Dihexa demonstrated significant reversal of learning deficits. These models are relevant to cholinergic deficit hypotheses of Alzheimer's disease, though they represent only one aspect of a multifactorial condition.

06 Dihexa vs Semax vs Selank

07 Protocol Notes

In published rodent studies, Dihexa has been administered via multiple routes including subcutaneous injection, intranasal delivery, and oral gavage. Its lipophilic nature makes oral absorption possible, unlike most peptides which are degraded in the GI tract. Research doses in rodent studies typically range from 1–10 mg/kg bodyweight.

The compound is stored as a lyophilised powder and reconstituted in sterile water or bacteriostatic water for injection-based administration. Stability data suggests good stability when stored at −20°C, with short-term (2–4 week) stability at 4°C.

08 Frequently Asked Questions